Why the study?
Does the automated chemiluminescence-based VWF:CB assay improve the diagnosis and classification of von Willebrand disease in patients undergoing diagnostic testing?
Does the automated chemiluminescence-based VWF:CB assay improve the diagnosis and classification of von Willebrand disease in patients undergoing diagnostic testing?
Answers are grounded in this paper and cite their sources.
The new automated VWF:CB assay improves the identification of types 1 and 3 VWD but requires algorithmic approaches to overcome its limitations in differentiating type 2A/2B from 2M VWD.
Although von Willebrand disease (VWD) identifies the most common inherited bleeding disorder, many laboratories and clinicians continue to struggle with its diagnosis or exclusion.1, 2 VWD arises from deficiency and/or defects of von Willebrand factor (VWF), an adhesive plasma protein essential for effective primary haemostasis.3 VWF possesses many functional properties, which essentially explains the heterogeneity in clinical symptoms and bleeding risk in VWD-affected patients, as well as diagnostic challenges. Although a comprehensive panel of tests is required to diagnose VWD, and to assign a VWD type,1-3 different experts may assign different value to different tests, different methodologies and/or different test panels. There has been substantial activity in VWD diagnostics of late. In terms of platelet glycoprotein Ib (GPIB) binding, there has been a recent expansion in assay methods potentially challenging the classical VWF ristocetin cofactor (VWF:RCo) assay,4 and prompting the International Society on Thrombosis and Hemostasis (ISTH) Scientific Standardization Committee (SSC) to develop an updated nomenclature to cover the many different methods.5 The VWF collagen binding assay (VWF:CB) reflects another activity of VWF, namely its ability to adhere to subendothelial matrix components. The importance of the VWF:CB in VWD diagnostics depends on your geographic locality. The VWF:CB is used by over 60% of laboratories involved in VWD diagnostics in Australia, a high proportion of such laboratories in Europe, but only a small proportion of such laboratories in North America (<10%), with the latter most likely related to regulatory restrictions rather than lack of utility.6 Notably, the use of the VWF:CB is strongly supported by the UK Haemophilia Directors organization.7 Our laboratory along with many others have reported on the value of the VWF:CB in VWD diagnostics. However, we have also reported that effective clinical utility cannot be assumed for all VWF:CB assays. Indeed, the clinical utility of any VWF:CB is a product of the assay design, including the assay format (ELISA, flow cytometry, etc), the type of collagen used (type I, type III, type IV, type VI, combinations, portions/fragments), the concentration of the collagen used and the manner in which it is attached to the solid assay phase.8, 9 The VWF:CB was first described in 1986,10 meaning it has now been a part of the VWD diagnostic landscape for over 30 years. We are entering a new phase for the VWF:CB, with the first automated assay now available, as originally published by our laboratory last year,11 and as further independently described by Stufano and colleagues in this issue of the journal.12 In brief, our published evaluation identified that the new automated assay (marketed commercially by Instrumentation Laboratories; Werfen IL, Barcelona, Spain) had both strengths and potential limitations. Notably, we did identify occasional errors with the new automated assay, which means the new test procedure is not totally error free; nevertheless, it was less error prone than our standard ELISA VWF:CB, as well as GPIB assays.11 Stufano and colleagues also noted at least one error with the new system in their study.12 Compared with our ELISA-based “reference” assay, the automated chemiluminescence-based assay showed reduced variability, and higher sensitivity to low levels of VWF; these features mean superior identification of types 1 and 3 VWD, as well as offering better discrimination between types 1 and 2 VWD.11 On the other hand, the automated assay seemed to have reduced ability to discriminate type 2A/2B VWD (meaning loss of high molecular weight [HMW] VWF) from type 2M VWD 11 (meaning dysfunctional VWF not associated with loss of HMW VWF3). This “differential” comparative utility in VWD diagnostics relates to the different methodologies employed (semiautomated ELISA vs automated chemiluminescence), as well as the different type and application of collagen used (the automated method uses a collagen fragment derived from type III collagen; the ELISA assay uses a type I/III collagen mixture product). The diagnosis of VWD requires many steps. In addition to clinical evaluation, and clinical evidence of personal and family bleeding history, laboratory testing should identify patterns suggestive of VWD, which should also be repeated for confirmation on a fresh sample. Repeat testing on a fresh sample should also be undertaken when test results are normal in a patient with strong suspicion of VWD. Repeat testing takes into account intrapatient variability (eg stress increases VWF levels), preanalytical issues (eg false low VWF levels in diluted or under-filled blood samples, or false loss of HMW VWF in serum or clotted plasma samples) and analytical limitations and errors (eg false low or false normal value with any given methodology). As mentioned, all VWF test methods (including the new automated VWF:CB assay) yield occasional false values.11, 12 However, the error rate with new automated VWF:CB assay is likely to be lower than many other VWF:CB methodologies, and indeed is expected to be less than many GP-Ib binding assays, especially classical VWF:RCo methods.2, 11 The new automated VWF:CB appears potentially superior to comparative VWF:CB assays in terms of assisting in the differential identification of types 1, 2 and 3 VWD, including the differentiation of type 1 vs 2A/B/M VWD.11, 12 The automated VWF:CB, however, may be less able to differentiate type 2A/B vs 2M VWD than comparative (eg ELISA) methods. Some examples of this were provided previously12 and are also highlighted here with some additional new data (Figure 1). As long as this limitation is noted, the automated VWF:CB still has clear and high clinical utility, and probably more clinical utility than many other VWF:CB assays currently in use.2, 8, 9 The importance of the need to differentiate type 2A vs 2M VWD is not entirely clear. There is some evidence that patients with 2M VWD suffer reduced bleeding severity than those with 2A.13, 14 It is also clear that 2M VWD is grossly underdiagnosed by most laboratories1, 14, 15; here, however, it needs to be emphasized that the diagnosis of VWD is often missed entirely or else is misrepresented as type 1 VWD, rather than 2A VWD. Finally, we need to recognize that 2M VWD does form a separate category of VWD,3 and if patients fit the classification, they should be so assigned. Indeed, the 2M VWD category is particularly important because it provides a category where patients who do not fulfill the criteria for types 1, 2A, 2B, 2N or 3 VWD can be placed; otherwise, these patients will forever remain “unclassified” VWD. Finally, the beauty of VWD diagnostics is that it includes strategies to diagnose VWD patients even when assay limitations exist. In the case of type 2M vs 2A/2B discrimination, or indeed 2M vs 1 discrimination, for example, there are always options. Our recommended algorithmic approach, useful irrespective of which VWF:CB is utilized, is detailed in Figure 2. So, irrespective of whether an ELISA VWF:CB is used, and this is one capable of type 2M vs 2A/2B discrimination, or else the automated chemiluminescence-based VWF:CB assay is used (with apparently more limited type 2M vs 2A/2B discrimination), discrimination of VWD type remains possible. In conclusion, a clinically valid VWF:CB, in experienced or at least knowledgeable hands, and as part of a comprehensive VWD test panel,3, 8, 16, 17 provides an excellent pathway towards correct diagnosis or exclusion of VWD. However, not all VWF:CB assays have the same clinical utility.8-11 A good working knowledge of the assays employed in any given laboratory, including both their strengths and limitations, must form part of every VWD diagnostic strategy. Another part of any VWD diagnostic strategy is recognizing that the first stage is clinical evaluation and that the second (initial) testing stage is only stage 2 of the overall diagnostic process. A third stage is represented by repeat testing for confirmation, with this sometimes involving different assays or additional laboratory tests. A fourth stage may also be required, involving more complex tests. These may include, for example, ristocetin-induced platelet agglutination [RIPA] to identify/exclude 2B or platelet type [PT] VWD), RIPA mixing to differentiate 2B/PT VWD, multimer analysis to identify retention/loss of HMW VWF and/or genetic analysis (Figure 2). The authors state that they have no interests which might be perceived as posing a conflict or bias. EJF wrote the original draft of this manuscript. SM and SO, respectively, performed some of the phenotypic testing and multimer analysis detailed in Figure 1. All authors contributed to revision of the manuscript and have approved the final version for publication. NSW Health Pathology is acknowledged for providing in-kind support. The views expressed herein are those of the authors and are not necessarily those of NSW Health Pathology.
No takes yet. Share an insight, caveat, or question.
Favaloro et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: